Enzolytics Statistics
Total Valuation
Enzolytics has a market cap or net worth of 2.90 million.
| Market Cap | 2.90M |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Enzolytics has 4.83 billion shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 4.83B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1,533.31% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.04% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.22 |
| PB Ratio | -4.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -704.71% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 140.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.50% in the last 52 weeks. The beta is 1.45, so Enzolytics's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -87.50% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 43.43 |
| Average Volume (20 Days) | 3,718,386 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Enzolytics had revenue of 46,590 and -1.03 million in losses. Loss per share was -4.76.
| Revenue | 46,590 |
| Gross Profit | 46,590 |
| Operating Income | -896,509 |
| Pretax Income | -1.03M |
| Net Income | -1.03M |
| EBITDA | -886,773 |
| EBIT | -896,509 |
| Loss Per Share | -4.76 |
Balance Sheet
The company has 5,760 in cash and 233,122 in debt, giving a net cash position of -227,362 or -0.00 per share.
| Cash & Cash Equivalents | 5,760 |
| Total Debt | 233,122 |
| Net Cash | -227,362 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -711,780 |
| Book Value Per Share | -0.63 |
| Working Capital | -652,937 |
Cash Flow
| Operating Cash Flow | -621,041 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,924.25% |
| Pretax Margin | -2,207.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Enzolytics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,458.29% |
| Shareholder Yield | -1,458.29% |
| Earnings Yield | -35.48% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on February 7, 2013. It was a reverse split with a ratio of 0.002.
| Last Split Date | Feb 7, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.002 |
Scores
Enzolytics has an Altman Z-Score of -714.55. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -714.55 |
| Piotroski F-Score | n/a |